Q-omics provides the consensus-scored IL23A profile across patient tissues and cancer cell-line models. IL23A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IL23A is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, IL23A RNA expression shows 17,410 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where IL23A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IL23A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IL23A survival associations across molecular data types. IL23A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IL23A RNA expression–survival associations across cancer types. High IL23A expression shows unfavorable associations in KIRC, ACC, KICH and KIRP, but favorable associations in HNSC and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IL23A RNA expression.
This table summarizes IL23A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IL23A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IL23A shows higher tumor expression in COAD, LUAD, READ, THCA, LUSC and STAD. The COAD box plot shows higher IL23A RNA expression in tumor versus normal tissue (log2 FC = +1.845, t-test p < 0.001).
This table shows molecular features associated with IL23A in patient tissues and cancer cell lines. In patient samples, IL23A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, IL23A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and PANCREAS.
